Status:
TERMINATED
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Social Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response,...
Eligibility Criteria
Inclusion
- Written Confirmed Consent,
- All patients meet the DSM IV criteria for generalized social anxiety disorder,
- A score ≥ 60 on the LSAS,
- male and female aged between 18 and 65 years
Exclusion
- Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,
- alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,
- any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,
- patients at risk of suicide
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00302770
Start Date
June 1 2006
End Date
December 1 2006
Last Update
January 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Utrecht, Netherlands